GoodRx Holdings, Inc.

Ladies and gentlemen, thank you for your standby and welcome to the GoodRx fourth quarter and full year 2021 earnings call. As a reminder, today's conference call is being recorded. I would now like to introduce your host for today's call, Whitney Notaro, Vice President of Investor Relations. Ms. Notaro, you may begin.

Thank you, Operator. Good afternoon, everyone, and welcome to GoodRx's earnings conference call for the fourth quarter and full year 2021. Joining me today are Doug Hirsch and Trevor Bezdek, our co-founders and co-chief executive officers, and Karsten Zohrman, our chief financial officer. Before we begin, I'd like to remind everyone that this call will contain forward-looking statements. All statements made on this call that do not relate to matters of historical fact should be considered forward-looking statements including statements regarding management's plans, strategies, goals, and objectives, our market opportunity, our anticipated financial performance, and the expected impact of COVID-19 on our business. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties, and other important factors. These factors may cause our actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Factors discussed in the risk factor section of our annual report on Form 10-K for the year ended December 31st, 2021 and our other filings with the Securities and Exchange Commission could cause actual results to differ materially from those indicated by the forward-looking statements made on this call. Any forward-looking statements represent management's estimates as of the date of this call, and we disclaim any obligation to update these statements, even if subsequent events cause our views to change. In addition, we may also reference certain non-gap metrics, which are reconciled to the nearest gap metric in the company's shareholder letter, which can be found on the overview page of our investor relations website at investors.gooderx.com. I'd also like to remind everyone that a replay of this call will become available there shortly as well. With that, I'll turn the call over to Doug.

Good afternoon, everyone, and thank you for joining us today. 2021 was another record year for GoodRx. We spent the year working hard to bring lower prescription and care prices to more people while also finding more ways to make GoodRx more helpful at additional points along more healthcare journeys. I'm proud to say that we made real progress and our impact has never been greater. During the year, millions of Americans used GoodRx to navigate their care. We made significant investments in our brand, substantially raising our unaided awareness. We created and acquired new products and consumer content and resources while strengthening our relationships with providers and deepening our relationships with pharmacies and others across the healthcare industry. Our platform has grown, as has our reach. We're especially excited about the delivery of our content initiatives around GoodRx Health and healthcare provider-focused platform extensions that help providers help their patients and support our pharma manufacturer solutions offering. We have now helped Americans save more than $35 billion on their prescriptions compared to the pharmacy cash price. This is an incredible milestone as we consider the impact of our business. In 2021 alone, more than 5 million of our users saved more than $500 compared to the pharmacy cash price, and our NPS increased to 90 among healthcare providers, equal to our high NPS with consumers. The incredible value we continue to deliver to consumers and providers led to another year of record results and record users. The greater our impact, the stronger our performance. I couldn't be more proud of our team. While millions of Americans continue to be impacted by COVID-19, we developed innovative and impactful ways to help. Early in 2021, when vaccines first became available, we quickly mobilized to build a vaccine guide, helping over 20 million Americans navigate when, where, and how to get vaccinated. This year, with the gradual rollout of the new COVID-19 antivirals, we quickly built a consumer-friendly online tracker showing availability at pharmacies nationwide. Many of the visitors to these services hadn't previously interacted with GoodRx, offering us an exciting opportunity to build a relationship with them. If this year has shown us anything, it's the importance of gratitude, and I could not be more grateful to work day in and day out with a team that is so fiercely dedicated to our mission and hard at work every day to make sure that we have an even greater impact in 2022. With that, I'll turn it over to Trevor to address key highlights from the quarter and our strategic priorities for 2022.